What are the indicators to evaluate the clinical results?

In the TRANSBIO study bad clinical evolution will be considered when patients show a progressive deterioration in renal function (with a significative increase of creatinine and/or proteinuria), show signs attributable to any kind of immunological response compatible with a rejection in biopsy, or an increase in strength of DSA expressed as Luminex MFI and with titters of more than 3000 UI.

Good clinical evolution will be considered for patients without rejection episodes, with a negative DSA, with a stable renal function and with no changes in their treatment.